Exelixis stock: Citizens lifts Exelixis stock target to USD 65.00 from USD 55.00

Published on 10/22/2026 at 20:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue reached USD 628.69 million in the second quarter. Exelixis stock costs EUR 58.21 on October 22, 2026 at 8:01 p.m. CEST against USD 65.00.

Analyst target and reporting date

Citizens lifted its Exelixis target from USD 55.00 to USD 65.00 on October 19, 2026.
Second-quarter revenue reached USD 628.69 million, up 10.60 percent year over year.
Exelixis stock costs EUR 58.21 at Lang & Schwarz on October 22, 2026 at 8:01 p.m. CEST.
Third-quarter 2026 results are scheduled for October 29, 2026.

EXEL, US30161Q1040, Illustration mit AI erstellt.

Citizens lifted its Exelixis target from USD 55.00 to USD 65.00 on October 19, 2026, while maintaining a Market Outperform rating, according to Investing.com. Exelixis stock was trading at EUR 58.21 at Lang & Schwarz on October 22, 2026 at 8:01 p.m. CEST.

Revenue reached USD 628.69 million

Exelixis reported USD 628.69 million in revenue for the second quarter of 2026, a 10.60 percent increase from the second quarter of 2025. Adjusted earnings per share reached USD 0.91, compared with a consensus estimate of USD 0.84, while revenue was below the USD 633.80 million estimate, according to Investing.com.

What does the USD 65.00 target imply?

The target sits 0.46 percent below the USD 65.30 Nasdaq quote at 2:03 p.m. ET on October 22, 2026. That contrast puts the latest Citizens revision close to the US market quotation, while the broader analyst picture remains more cautious: MarketBeat reported a Hold consensus from 20 ratings firms and an average target of USD 51.50 on October 20, 2026.

October 29 results set the next date

Exelixis will release third-quarter 2026 results after the US market close on October 29, 2026, followed by a conference call at 5:00 p.m. ET. The company announced the date in a release dated October 15, 2026, published through Exelixis.

The Nasdaq quote put Exelixis at a market capitalization of USD 16.4 billion and a trailing P/E ratio of 20.46 on October 22, 2026. Its 52-week range was USD 36.00 to USD 65.42, leaving the latest US quotation USD 0.12 below the high.

Price and target remain close

Citizens points to upcoming oncology data as part of its revised view, while the second-quarter numbers combine double-digit revenue growth with a revenue miss against consensus. The October 29 reporting date will provide the next quantified test of that balance.

The further course of trading is shown by the continuously updated real-time quote of Exelixis stock.